Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Web Exclusives

In patients with stage III non–small-cell lung cancer (NSCLC) whose disease did not progress after 2 or more cycles of platinum-based chemoradiotherapy, use of durvalumab as consolidation therapy significantly improved progression-free survival.
According to the results of a recent phase 2 clinical trial, treatment with a regimen of dabrafenib, an oral BRAF inhibitor, plus trametinib, an MEK inhibitor, is effective and tolerable in previously untreated patients with BRAF V600E‒mutated metastatic non–small-cell lung cancer (NSCLC).
Rovalpituzumab tesirine, an investigational antibody-drug conjugate that targets delta-like protein 3, shows encouraging single-agent efficacy with a manageable safety profile in the treatment of patients with recurrent small-cell lung cancer, according to recently published results.
At 10-year follow-up, investigators observed similar outcomes with exemestane alone and sequential tamoxifen/exemestane in the phase 3 TEAM trial of postmenopausal women with hormone receptor (HR)-positive early breast cancer.
The results of a recent gene-sequencing analysis identify new pathogenic mutations associated with an increased risk for breast cancer.
The extended use of anastrozole for 3 years beyond 5 years of sequential therapy did not improve disease-free survival or overall survival in postmenopausal women with hormone receptor–positive, early breast cancer.
The addition of carboplatin increases response in patients with triple-negative breast cancer without pathogenic BRCA1 and BRCA2 mutations.
Prolonged use of hormonal contraceptives slightly increases the risk for breast cancer.
Intraventricular HER2 CAR T-cell therapy may be an option for patients with HER2+ breast cancer and brain metastasis.
In the phase 3 OlympiAD trial, treatment with olaparib significantly improved progression-free survival and reduced the risk for disease progression or death compared with standard chemotherapy in women with HER2-negative, BRCA-mutated metastatic breast cancer.
Page 4 of 18
Results 31 - 40 of 180